1 research outputs found
Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer
BMS-641988 (<b>23</b>) is a
novel, nonsteroidal androgen
receptor antagonist designed for the treatment of prostate cancer.
The compound has high binding affinity for the AR and acts as a functional
antagonist <i>in vitro</i>. BMS-641988 is efficacious in
multiple human prostate cancer xenograft models, including CWR22-BMSLD1
where it displays superior efficacy relative to bicalutamide. Based
on its promising preclinical profile, BMS-641988 was selected for
clinical development